Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

1.800 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 Next >
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the Jefferies London Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
From Nuvation Bio Inc.
Via Business Wire
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the Cantor Global Healthcare Conference
From Nuvation Bio
Via Business Wire
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
From Nuvation Bio Inc.
Via Business Wire
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END 
Via FinancialNewsMedia
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
From Nuvation Bio Inc.
Via Business Wire
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
From Nuvation Bio Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.